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Background: Epinephrine auto-injectors are the standard first aid treatment for anaphylaxis. Intramuscular delivery
into the anterolateral aspect of the thigh is recommended for optimal onset of action of epinephrine. The most
frequently prescribed auto-injector in North America and Canada is the EpiPen®, which has a needle length of
15.2 mm. Currently, it is unknown whether this needle length is adequate for intramuscular delivery of epinephrine
in adult patients at risk of anaphylaxis.
Methods: One hundred consecutive adult patients with confirmed food allergy requiring an epinephrine auto-injector
were recruited. Skin to muscle depth (STMD) at the right mid-anterolateral thigh was measured using ultrasound
under minimal (min) and maximum (max) pressure. The EpiPen® needle length was considered adequate if
STMDmax was ≤15.2 mm. Baseline characteristics including age, gender, ethnicity, and body mass index (BMI)
were compared in patients with STMDmax ≤15.2 mm vs. >15.2 mm.
Results: The EpiPen® needle length of 15.2 mm was inadequate for intramuscular delivery in 19 of the 100
enrolled patients (19%), all of whom were female; 28% of women had a STMDmax >15.2 mm. The mean STMDmax
in the ≤15.2-mm and >15.2-mm groups were 9 ± 4 mm and 20 ± 4 mm, respectively (p = 0.0001). Linear
regression analysis found BMI to be significantly associated with STMDmax after adjusting for age (p < 0.001).
Conclusions: The needle length of the epinephrine auto-injectors may not be adequate for intramuscular
delivery of epinephrine in a large proportion of women with food allergy; this may impact morbidity and
mortality from anaphylaxis in this patient population.
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Anaphylaxis is a serious allergic reaction that is rapid in
onset and may cause death [1]. Although there are sev-
eral causes of fatal anaphylaxis, food allergy is one of the
most common [2]. Epinephrine is recommended as the
initial treatment of choice for anaphylaxis [1,3]. A delay
in epinephrine administration may contribute to an
increased risk of death [2]. Previous studies have demons-
trated that the site and route of administration of epine-
phrine significantly affect both its peak concentration and* Correspondence: hlkimkw@gmail.com
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unless otherwise stated.time to onset of action. In children, intramuscular adminis-
tration of epinephrine resulted in a higher peak concentra-
tion and shorter time at which peak concentration was
achieved than subcutaneous administration [4]. A subse-
quent study in adult males showed that peak plasma epi-
nephrine concentrations were significantly higher after
intramuscular injection into the thigh than following intra-
muscular or subcutaneous administration into the upper
arm [5]. Therefore, the World Allergy Organization recom-
mends that, for the treatment of anaphylaxis, epinephrine
(0.01 mg/kg of a 1:1000 [1 mg/mL] solution to a maximum
of 0.5 mg in adults and 0.3 mg in children) be administered
intramuscularly in the mid-anterolateral thigh [3].
Outside of the hospital setting, epinephrine auto-
injectors have become the mainstay of therapy for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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most commonly prescribed epinephrine auto-injector
for adult patients is the EpiPen® [6], which has a needle
length of 15.2 mm [7]. Given the increasing prevalence
of obesity in North America, two studies have examined
whether the design of available epinephrine auto-injectors
is adequate for delivering epinephrine intramuscularly to
adult patients [8,9]. Song et al. retrospectively analyzed the
skin-to-muscle distance in the anterolateral aspect of the
thigh in 50 men and 50 women who had undergone com-
puted tomography (CT) of the thighs for other medical rea-
sons [9]. The investigators found that, in a large proportion
of women, the EpiPen® may not deliver epinephrine to the
intramuscular tissue. Bhalla et al. prospectively assessed
depth-to-muscle measurements of the vastus lateralis in
low-acuity general emergency department patients and
found that the current epinephrine auto-injector needle
length is inadequate for intramuscular administration,
particularly in women [8]. The current study was per-
formed to examine whether the needle length of the
EpiPen® is appropriate for injecting epinephrine into
the intramuscular space in men and women at risk of
anaphylaxis from food allergy. To our knowledge, this
is the first study of this nature to be conducted in adult
patients at risk of anaphylaxis.
Methods
One hundred consecutive adult patients with confirmed
food allergy who required epinephrine auto-injector pre-
scriptions in an allergist’s office were included in thisFigure 1 Ultrasound images in a patient with A. minimal pressure anstudy. The subjects were both new and follow-up pa-
tients who were assessed from July 2012 to November
2013. All subjects agreed to participate in the study.
Demographic information including patient race, sex,
age, weight and height was collected and ultrasound im-
ages of the anterolateral aspect of the mid-right thigh
were taken in the standing position using the Sonosite
Titan® ultrasound machine. Measurements were ob-
tained for the same anatomical location in all patients.
Skin-to-muscle depth (STMD) at the right mid-
anterolateral thigh was measured by a single operator
(a physician) under minimal (min) and maximum
(max) pressure. Minimal pressure was defined as “just
enough” pressure to obtain an adequate image, and
maximum pressure was defined as pressure mimicking
that required for proper auto-injection, which is esti-
mated to be approximately 2 to 8 lbs [10]. The phys-
ician visualized the soft tissue while performing the
compression and froze the screen for measurement
when the soft tissue was maximally compressed. Mea-
surements in both the minimal and maximum com-
pression views in frozen screen mode were recorded
(Figure 1). Each image screen shot also included the
femur for reference. All patients provided written, in-
formed consent prior to participating in this study.
The Lawson Health Research Institute Research Ethics
Board at Western University in London, Ontario,
Canada approved the study.
The auto-injector needle length was considered ad-
equate if STMDmax was ≤15.2 mm. Our primary goald B. maximal pressure.
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STMDmax >15.2 mm since these subjects are at risk of
receiving epinephrine subcutaneously, rather than intra-
muscularly as currently recommended. Hence, the pri-
mary outcome variable was the proportion of subjects
with a STMDmax >15.2 mm. A secondary variable was
the proportion of women with a STMDmax >15.2 mm.
The participants were divided into two groups based on
whether their STMDmax was ≤15.2 mm or >15.2 mm.
Baseline characteristics of participants were analyzed
using the Student’s t-test/Mann Whitney U test for con-
tinuous variables and Chi-square/Fisher’s exact test for
categorical variables. Multivariable linear regression ana-
lysis was used to identify factors, including sex, age,
weight, height, BMI, that were significantly associated
with a STMDmax >15.2 mm in both the entire patient
cohort and in females. The percent compression of the
STMD and the proportions of female patients with a
STMDmax less than 15.2 mm, 20 mm, 25 mm and
30 mm were also assessed.
Results
The STMDmax was used to determine if needle length
was adequate, as this most closely mimics patient charac-
teristics at the time of administration of the epinephrine
auto-injector. The subjects ranged from 18 to 72 years of
age. Nineteen of the 100 patients included in this study
(19%) had a STMDmax >15.2 mm; 28% of women had a
STMDmax >15.2 mm (Figure 2). None of the men in this
study had a STMDmax >15.2 mm.
Sex, weight, height, BMI, and mean STMD differed sig-
nificantly between subjects with a STMDmax less than/equal
to vs. >15.2 mm (all p < 0.05, Table 1). Weight and BMI
were higher, and height was lower, in those subjects with a
STMDmax >15.2 mm. In women, weight, BMI and mean
STMD differed significantly between the two comparisonFigure 2 Proportion of women with STMDmax less than/equal
to or >15.2 mm.groups (all p < 0.05, Table 2). Multivariable linear regression
analysis found BMI (p = 0.001) to be significantly associated
with STMD at both minimal and maximal pressure after
adjusting for age (Figure 3). Mean change in STMD with
pressure was 11% for all subjects and 16% for women.
This change was less than the 25% estimated in a
previous study [8]. The percentage of women with a
STMDmax ≤15.2 mm, <20 mm, <25 mm and <30 mm
was 72%, 91%, 96% and 99%, respectively. Only one
woman had a STMDmax ≥30 mm (Table 3).
Discussion
The results of this study demonstrate that although the
needle length of a standard epinephrine auto-injector is
likely adequate for intramuscular delivery of epinephrine
in many patients at risk of anaphylaxis, it does not
appear to be adequate for a significant proportion of
women. These findings are consistent with those of a
2005 study conducted in patients who had undergone
CT of their thighs for other medical reasons, as well as a
2013 study of low-acuity patients in the emergency de-
partment setting [8,9]. The former study assessed the
CT scans of the legs of patients who had been investi-
gated for deep vein thrombosis with or without pulmon-
ary embolus [9]. A number of CT scans (180) were
retrospectively reviewed and the first 100 were included
in the study if the patient’s height and weight were also
available. No images or measurements of the STMD
with compression were completed in these subjects.
Based on testing of one male and one female subject,
the investigators estimated that there would be a 25% re-
duction in the STMD with 8 pounds of pressure applied
to the leg. Also, the investigators used a needle length of
14.3 mm to determine adequacy of the epinephrine
auto-injector for intramuscular administration. The 2013
study conducted in the emergency department setting
was also performed in patients who were not at risk of
anaphylaxis [8]. Subjects were recruited prospectively, in
a non-consecutive fashion, only during the time when
study investigators were available. Ultrasound measure-
ments were completed with and without pressure to
simulate the pressure required to trigger the auto-
injector device. In that study a needle length of 15.9 mm
was used. Also, the ultrasound images were taken at the
spot where the hand laid to rest on the lateral thigh, fol-
lowing the directions in the EpiPen® product monograph
[6]. It is important to note that our study is the first to
be completed in adult patients with food allergy who
were at risk of anaphylaxis. All patients required an epi-
nephrine auto-injector and were recruited into the study
consecutively. This is also the first study to assess the
impact of applying pressure on the site of auto-injector
application in order to measure STMDmax at the mid-
anterolateral thigh in these at-risk patients. We believe
Table 1 Baseline characteristics of study population
Characteristic Total, n = 100 Patients with STMD minimum P value* Patients with STMD maximum P value*
≤15.2 mm, n = 68 >15.2 mm, n = 32 ≤15.2 mm, n = 81 >15.2 mm, n = 19
Age (years), mean (SD) 37 (14) 35 (15) 41 (13) 0.01 36 (14) 42 (14) 0.06
Males, n (%) 31 (31) 31 (45) 0 (0) 0.00001 31 (37) 0 (0) 0.001
Caucasian, n (%) 89 (89) 59 (87) 30 (93) 0.495 71 (88) 18 (95) 0.685
Weight (kg), mean (SD) 76 (19) 73 (19) 83 (18) 0.014 74 (18) 89 (19) 0.003
Height (m), mean (SD) 1.7 (0.1) 1.69 (0.1) 1.64 (0.1) 0.020 1.69 (0.1) 1.64 (0.1) 0.02
BMI (kg/m2), mean (SD) 27 (6) 25 (5) 31 (7) 0.001 26 (5) 33 (8) 0.0001
STMD max (mm), mean (SD) 11 (6) 8 (3) 17 (4) 0.0001 9 (3) 19 (4) 0.0001
STMD min (mm), mean (SD) 13 (7) 9 (3) 21 (6) 0.0001 11 (5) 23 (7) 0.0001
STMD% compression, mean (SD) 11 (10) 11 (10) 18 (10) 0.002 13 (11) 15 (9) 0.41
*P-value calculated by Student’s t test or Chi square test/Fisher’s exact test.
SD: standard deviation; BMI: body mass index; STMDmin: skin-to-muscle depth with minimal pressure; STMDmax: skin-to-muscle depth with maximal pressure.
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of the auto-injector is adequate for intramuscular ad-
ministration at the proper site of injection [1,3]. We
used the needle length that is published in the EpiPen®
patent at 15.2 mm [7]. We identified that, with pressure,
the subcutaneous space was compressed by only 11%,
which is significantly less than the estimated 25% in the
study by Song et al. [8].
Two studies, one completed in adults and one in chil-
dren, have suggested that intramuscular administration
leads to higher serum levels of epinephrine more rapidly
than subcutaneous injections [4,5]. In fact, intramuscular
administration of epinephrine into the thigh has become
the standard recommended treatment for anaphylaxis
due to the results of the adult study [5], which included
13 men in a 6-way crossover design. However, it is im-
portant to note that ultrasound was not used to confirm
whether epinephrine was truly delivered to the appropri-
ate tissue compartment, and no female subjects were
included in this study. It is possible that the pharmaco-
kinetics and pharmacodynamics of epinephrine may dif-
fer between men and women. Future studies shouldTable 2 Baseline characteristics of females in the study
Characteristic Total, n = 69 Patients with STMD min
≤15.2 mm, n = 37 >15.2
Age (years), mean (SD) 37 (13) 33 (12) 41 (13
Caucasian, n (%) 61 (88) 31 (82) 30 (94
Weight (kg), mean (SD) 73 (17) 64 (12) 83 (18
Height (m), mean (SD) 1.6 (0.1) 1.62 (0.1) 1.64 (0
BMI (kg/m2), mean (SD) 27 (7) 24 (4) 31 (7)
STMD max (mm), mean (SD) 13 (5) 10 (2) 17 (4)
STMD min (mm), mean (SD) 16 (7) 11 (2) 21 (6)
STMD% compression, mean (SD) 16 (11) 14 (11) 18 (10
*P-value calculated by Student’s t test or Chi square test/Fisher’s exact test.
SD: standard deviation; BMI: body mass index; STMDmin: skin-to-muscle depth withinclude women to determine if such gender differences
are present. Also, there are no human randomized con-
trolled studies assessing the effects of epinephrine in the
clinical setting of anaphylaxis. These studies would be
practically challenging and may be considered unethical
taking into account the studies noted above [4,5].
Similar to the findings of Bhalla et al. [8] and Song
et al. [9] discussed earlier, our study found that only
women were at risk of subcutaneous injections of epi-
nephrine. Certainly, however there will be both men and
women with anaphylaxis who will have a STMDmax
greater than the needle lengths of the currently available
epinephrine auto-injectors. Importantly, our study is the
first to use the EpiPen® needle length that is published
in the formal patent submission. Ideally, ultrasounds
should be performed in all patients prescribed auto-
injectors to assist in identifying patients at risk of sub-
cutaneous injections. For these patients, an alternative
method of epinephrine injection could be to provide
vials of epinephrine and syringes with longer needles.
However, this approach may potentially lead to incorrect
dosing and slower delivery of the epinephrine injectionimum P value* Patients with STMD maximum P value*
mm, n = 32 ≤15.2 mm, n = 50 >15.2 mm, n = 19
) 0.009 35 (12) 43 (14) 0.03
) 0.27 43 (86) 18 (95) 0.29
) 0.001 67 (12) 89 (19) 0.001
.1) 0.16 1.63 (0.1) 1.64 (0.1) 0.71
0.0001 25 (4) 33 (8) 0.001
0.0001 11 (3) 20 (4) 0.0001
0.0001 13 (4) 23 (7) 0.0001
) 0.11 16 (11) 15 (9) 0.53
minimal pressure; STMDmax: skin-to-muscle depth with maximal pressure.
Figure 3 Box plots showing the differences in BMI between the two comparison groups. BMI: body mass index; STMD: skin-to-muscle depth.
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into the thigh may lead to deeper injections. For ex-
ample, increased compression or more “hand swing”
may trigger the auto-injector to deliver epinephrine
more deeply [10]. The availability of auto-injector
devices with longer needle lengths would be another
potential solution to this problem. In the United Kingdom,
there is an epinephrine device available which has a 25-mmlong needle [12]. At this needle length, epinephrine would
be injected intramuscularly in 96% of our female subjects.
If the auto-injector had a 30-mm needle length, 99% of
women would appropriately receive the epinephrine
intramuscularly (Table 3). However, it is likely that at a
certain length, the needle would be too long for some
patients, leading to injection of the epinephrine into
the bone.
Table 3 Proportion of females with STMDmax at different
thresholds
Groups Number of women, n (%)
≤15.2 mm 50 (72%)
<20 mm 63 (91%)
<25 mm 66 (96%)
<30 mm 68 (99%)
≥30 mm 1 (1%)
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rine intramuscularly are unknown. Our major concern is
that patients with a STMDmax greater than the auto-
injector needle length will not attain adequate epineph-
rine levels rapidly enough to treat anaphylaxis, thereby
increasing the risk of death. At present, there are no
published studies or case reports to confirm this con-
cern. Nonetheless, studies assessing deaths from ana-
phylaxis have identified that many deaths occur in
women, and that some of these women were at risk of
having a STMDmax greater than 15.2 mm [2]. Also, a
media report from 2011 suggests that a longer epineph-
rine auto-injector needle length may have saved the life
of a 19-year-old female in England who died of anaphyl-
axis from food allergy [13]. The European Medicines
Agency is currently reviewing epinephrine auto-injectors
to assess whether the needle length is appropriate for
intramuscular delivery [14].
The main strengths of this study were that the patients
included adults at risk of anaphylaxis, the subjects were
recruited consecutively, the STMDmax was used as the
primary variable, the proper length of the EpiPen® needle
was used based on the patent submission for the prod-
uct and ultrasound measurements were taken in the rec-
ommended location for epinephrine auto-injector
application. The findings of this paper confirm that a
significant number of women at risk of anaphylaxis are
at risk of injecting epinephrine into the subcutaneous
space and, therefore, may not be receiving the proper
benefits of this potentially life-saving medication.
Our study has some limitations. Firstly, we only esti-
mated the pressure and the depth of using an epineph-
rine auto-injector with the ultrasound probe. A more
accurate method of applying pressure would be to
actually measure the pressure required to trigger an
auto-injector and then to perform the ultrasound with a
similar pressure. However, even with consistent pressure
applied, the surface areas of the ultrasound probe and
the epinephrine auto-injectors are different. This may
lead to varying depths of compression. Also, our esti-
mate of compression will likely be different than the
“real-life” compression that occurs when a patient actu-
ally uses an auto-injector. Patients will most likely use
variable levels of force when self-administering the auto-injector. As well, the ultrasound measurements were
completed with subjects in the standing position only as
this is the recommended position in the images of the
EpiPen® product monograph. However, the EpiPen® could
be injected in the lying or sitting positions in differing clin-
ical situations. Future studies could complete ultrasound
measurements in these different body positions.
Secondly, one unblinded physician performed all of
the ultrasounds in this study. Although this may lead to
more consistent test results, it may have also lead to
observer bias among the tests that were completed.
Thirdly, the study was performed in one clinic in South-
ern Ontario, Canada. Although the patients in this study
are likely representative of adults with food allergy in
Southern Ontario, they may not be representative of pa-
tients from other geographic and socioeconomic areas.
This may explain the difference between our findings
and those of Bhalla et al. [8] who found that 31% of their
entire patient cohort and 54% of their female subjects
were “failure risks” (i.e., patient muscle depth exceeded
the 15.9-mm length of the auto-injector needle). It is im-
portant to note that this latter study was conducted in
Ohio, USA, where the prevalence of obesity is approxi-
mately 30% [15]. Ideally, a multicentre study including
patients from various geographic and socioeconomic
areas would be the preferred approach for studying this
issue.
Finally, we did not formally assess whether another avail-
able epinephrine auto-injector, Allerject®, with a needle
length of 15.7 mm would have comparable results. We did
identify two patients in our study that would have had the
Allerject®, but not the EpiPen®, auto-injector reach the
intramuscular space. As future products become available,
the needle lengths, real injection depths and true function
of these devices should be considered before they are
prescribed.Conclusions
To our knowledge, this is the first study evaluating the ad-
equacy of the epinephrine auto-injector needle length to
deliver epinephrine intramuscularly in adult patients at risk
of anaphylaxis. Our study suggests that in up to 19% of
adult patients, and in approximately 28% of adult females,
the commercially available epinephrine auto-injectors will
potentially not reach the intramuscular space. In these pa-
tients, the epinephrine auto-injectors may not be ideal for
the rapid treatment of anaphylaxis. Further research to de-
termine the clinical implications of inadequate needle
lengths of epinephrine auto-injectors is recommended.
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